Global Radiopharmaceutical/Nuclear Medicine Market Market Report By Product (Diagnostic Products (SPECT, PET), Therapeutic Products (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application (Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumor, Others), By End-use (Hospitals & Clinics, Diagnostic Centers, Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2023-2032

As per this study, the Global Radiopharmaceutical/Nuclear Medicine Market was valued USD 10.55 BN (by revenue) in 2021 and is anticipated to reach USD 27.65 BN by 2028 with a CAGR of 12.8%.
 
Radiopharmaceutical/nuclear medicine refers to a radioactive drug used for monitoring and treating patients suffering from cancer, heart related problems, and neural issues. The trace amount of radioisotope present in the medicine binds the organic compound, which is later conveyed, to the target cell, tissue or organ. The rays emitted by radioisotope are detected by specific imaging device. The gamma rays are used for diagnostic purpose whereas short-range alpha or beta rays are used for treatment purpose.
 
Market Dynamics
 
Rising commonness of cancer and cardiovascular diseases has led the demand for nuclear medicine. Increasing spending on healthcare followed by rising awareness regarding the medicine is also contributing the market growth. Owing to non-invasive treatment, radiopharmaceutical/nuclear medicine is gaining major traction. However, short-term time of nuclear medicine is likely to hinder the market growth.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of radiopharmaceutical/nuclear medicine.
 
Market Segmentation
 
The broad radiopharmaceutical/nuclear medicine market has been sub-grouped into type, and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Product

• Diagnostic Products (SPECT, PET)
• Therapeutic Products (Alpha Emitters, Beta Emitters, Brachytherapy)

 
By Application

• Cardiology
• Neurology
• Oncology
• Thyroid
• Lymphoma
• Bone Metastasis
• Endocrine Tumor
• Others

 
By End-use

• Hospitals & Clinics
• Diagnostic Centers
• Others

 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for radiopharmaceutical/nuclear medicine in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Global Radiopharmaceutical/Nuclear Medicine Market Share by Region (Representative Graph)
 

 
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the radiopharmaceutical/nuclear medicine market include Eckert & Ziegler, Mallinckrodt, GE Healthcare, Jubilant Life Sciences Ltd., Nordion (Canada), Inc., Bracco Imaging S.P.A., IRE, the Australian Nuclear Science and Technology Organization, NTP Radioisotopes SOC Ltd., Eczacıbaşı-Monrol, Lantheus Medical Imaging, Inc., Cardinal Health.. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.